U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H26ClN5O3
Molecular Weight 479.959
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-536924

SMILES

CC1=C2N=C(NC2=CC(=C1)N3CCOCC3)C4=C(NC[C@@H](O)C5=CC=CC(Cl)=C5)C=CNC4=O

InChI

InChIKey=ZWVZORIKUNOTCS-OAQYLSRUSA-N
InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19789352 https://www.ncbi.nlm.nih.gov/pubmed/19258511

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. BMS-536924 has been shown to inhibit the catalytic activity of IGF-1R and its down stream signaling components such as Akt and MAPK in cells; it also inhibits proliferation in a wide variety of human cancer cell lines including, colon, breast, lung, pancreas, prostate, sarcoma and multiple myeloma. In vivo, BMS-536924 inhibits tumor growth in an IGF-1R-dependent tumor model (IGF-1R Sal) as well as in a broad range of human tumor xenografts.

Originator

Curator's Comment: # Bristol-Myers Squibb

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
2013 Mar
The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.
2014 Feb
BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.
2015
Patents

Sample Use Guides

Mice: oral administration of 70 mg/kg BMS-536924 significantly inhibits tumor growth (TGBC-1TKB cells) inoculated in nude mice.
Route of Administration: Oral
Pre-incubation of MCF10A cells with 1uM BMS-536924 completely blocked the ability of IGF-I to stimulate IGFIR phosphorylation
Name Type Language
BMS-536924
Common Name English
2(1H)-PYRIDINONE, 4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-
Systematic Name English
(S)-4-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(4-METHYL-6-MORPHOLINO-1H-BENZO(D)IMIDAZOL-2-YL)PYRIDIN-2(1H)-ONE
Systematic Name English
4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-2(1H)-PYRIDINONE
Systematic Name English
BMS 536924 [WHO-DD]
Common Name English
Code System Code Type Description
CAS
468740-43-4
Created by admin on Sat Dec 16 04:40:29 GMT 2023 , Edited by admin on Sat Dec 16 04:40:29 GMT 2023
PRIMARY
FDA UNII
40E3AZG1MX
Created by admin on Sat Dec 16 04:40:29 GMT 2023 , Edited by admin on Sat Dec 16 04:40:29 GMT 2023
PRIMARY
PUBCHEM
135440466
Created by admin on Sat Dec 16 04:40:29 GMT 2023 , Edited by admin on Sat Dec 16 04:40:29 GMT 2023
PRIMARY